TY - JOUR T1 - CANCER CHEMOTHERAPY AND DRUG METABOLISM JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1083 LP - 1096 DO - 10.1124/dmd.105.004374 VL - 33 IS - 8 AU - David S. Riddick AU - Chunja Lee AU - Shairoz Ramji AU - Edwin C. Chinje AU - Rachel L. Cowen AU - Kaye J. Williams AU - Adam V. Patterson AU - Ian J. Stratford AU - Charles S. Morrow AU - Alan J. Townsend AU - Youssef Jounaidi AU - Chong-Sheng Chen AU - Ting Su AU - Hong Lu AU - Pamela S. Schwartz AU - David J. Waxman Y1 - 2005/08/01 UR - http://dmd.aspetjournals.org/content/33/8/1083.abstract N2 - Drug-metabolizing enzymes and drug transporters are key determinants of the pharmacokinetics and pharmacodynamics of many antineoplastic agents. Metabolism and transport influence the cytotoxic effects of antineoplastic agents in target tumor cells and normal host tissues. This article summarizes several state-of-the-art approaches to enhancing the effectiveness and safety of cancer therapy based on recent developments in our understanding of antineoplastic drug metabolism and transport. Advances in four interrelated research areas presented at a recent symposium sponsored by the Division for Drug Metabolism of the American Society for Pharmacology and Experimental Therapeutics (Experimental Biology 2004; Washington D.C., April 17–21, 2004) are discussed: 1) interactions of anthracyclines with drug-metabolizing enzymes; 2) use of hypoxia-selective gene-directed enzyme prodrug therapy (GDEPT) in combination with bioreductive prodrugs; 3) synergy between glutathione conjugation and conjugate efflux in conferring resistance to electrophilic toxins; and 4) use of cytochromes P450 as prodrug-activating enzymes in GDEPT strategies. A clear theme emerged from this symposium: drug metabolism and transport processes can be modulated and exploited in ways that may offer distinct therapeutic advantages in the management of patients with cancer. The American Society for Pharmacology and Experimental Therapeutics ER -